This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
All content for Condensed IP is the property of Randy Noranbrock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
Magema Technology v. Phillips 66 (Fed. Cir., September 8, 2025) 2024-1342
Condensed IP
12 minutes
1 month ago
Magema Technology v. Phillips 66 (Fed. Cir., September 8, 2025) 2024-1342
This opinion concerns an appeal from a district court ruling in a patent infringement case between Magēmā Technology LLC and Phillips 66. Magēmā Technology, which holds a patent for desulfurizing heavy marine fuel oil (HMFO), sued Phillips 66 for infringement. The core issue on appeal concerns Phillips 66's improper and prejudicial argument at trial that ISO 8217 standards required actual testing data for fuel compliance, despite previously telling Magēmā that such testing was dangerous and e...
Condensed IP
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
